Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.76 |
| ▸ | MEN1 | O00255 | 4/20 | 0.76 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.57 |
| ▸ | MMP8 | P22894 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10495986 | 0.99 | KMT2A (0.74) | KMT2AMEN1CYP19A1L3MBTL1ALDH1A1 | |
| SCHEMBL3973449 | 0.92 | MEN1 (0.72) | KMT2AMEN1CYP19A1L3MBTL1ALDH1A1 | |
| SCHEMBL4005831 | 0.88 | MEN1 (0.74) | KMT2AMEN1CYP19A1L3MBTL1ALDH1A1 | |
| Dinsed SCHEMBL1814194 | 0.87 | KMT2A (1.00) | KMT2AMEN1CYP19A1L3MBTL1ALDH1A1 | |
| SCHEMBL18977029 | 0.86 | KMT2A (0.56) | KMT2AMEN1CYP19A1L3MBTL1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10406062 | 0.85 | ALDH1A1 (0.56) | KMT2AMEN1CYP19A1L3MBTL1ALDH1A1 | |
| SCHEMBL7035347 | 0.84 | TSHR (0.65) | KMT2AMEN1CYP19A1ALDH1A1POLB | |
| SCHEMBL2034554 | 0.82 | KMT2A (0.78) | KMT2AMEN1CYP19A1L3MBTL1ALDH1A1 | |
| SCHEMBL27625297 | 0.82 | KMT2A (0.83) | KMT2AMEN1CYP19A1L3MBTL1ALDH1A1 | |
| SCHEMBL3025870 | 0.82 | KMT2A (0.83) | KMT2AMEN1CYP19A1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019493-B1 | MODIFIED BET-PROTEIN INHIBITING DIHYDROCHINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | Bayer Pharma AG (DE) | 2017-06-14 | — | — | EP | disclosed |
| US-20160176867-A1 | MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | disclosed |
| US-20160176867-A1 | MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | disclosed |
| CN-105518001-A | MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | Bayer Pharma AG | 2016-04-20 | — | — | CN | disclosed |
| WO-2015193229-A1 | BET-PROTEIN INHIBITING 1,4-DIHYDROPYRIDO[3,4-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015193229-A1 | BET-PROTEIN INHIBITING 1,4-DIHYDROPYRIDO[3,4-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-23 | — | — | WO | disclosed |
| CN-100528876-C | Pyrrazolo-pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | CN | disclosed |
| EP-1603884-A4 | PYRIDINE, PYRIMIDINE, QUINOLINE, QUINAZOLINE, AND NAPHTHALENE UROTENSIN-II RECEPTOR ANTAGONISTS. | ENCYSIVE PHARMACEUTICALS INC (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7378417-B2 | Pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7320989-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| CN-1902185-A | Thiazolidinones, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2007-01-24 | — | — | CN | disclosed |
| EP-1678153-A1 | THIOZOLIDINONES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005123738-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | US | disclosed |
| EP-1603884-A2 | PYRIDINE, PYRIMIDINE, QUINOLINE, QUINAZOLINE, AND NAPHTHALENE UROTENSIN-II RECEPTOR ANTAGONISTS. | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005042505-A1 | THIOZOLIDINONES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-12 | — | — | WO | disclosed |
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-10 | — | — | US | disclosed |
| US-20040186102-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004078114-A2 | PYRIDINE, PYRIMIDINE, QUINOLINE, QUINAZOLINE, AND NAPHTHALENE UROTENSIN-II RECEPTOR ANTAGONISTS. | ENCYSIVE PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | PLK2, PLK4, PDXK | KMT2A 849/4885MEN1 3850/4885CYP19A1 2128/4885 |
| US-20160176867-A1 | MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | BRD4, BRDT, BET1 | KMT2A 658/4885MEN1 1355/4885CYP19A1 787/4885 |
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | P2RX3, P2RX1, P2RX5 | KMT2A 3706/4885MEN1 2675/4885CYP19A1 2174/4885 |
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | KMT2A 4263/4885MEN1 2624/4885CYP19A1 3550/4885 |
| US-20040186102-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | KMT2A 4263/4885MEN1 2624/4885CYP19A1 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.